Anika Therapeutics reports on Cingal(R) 13-01 study clinical trial top line data
Anika announced completion of enrollment in the Cingal 13-02 study, an open-label, follow-on study to the Cingal 13-01 study, to evaluate safety of a repeat injection of cross-linked sodium hyaluronate combined with triamcinolone hexacetonide (Cingal) intended to provide symptomatic relief of OA. April 17, 2015